procarbazine has been researched along with Malignant Melanoma in 38 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this randomized four-arm phase III study was to evaluate whether there is a difference in activity between regimens containing dacarbazine and regimens without dacarbazine in metastatic melanoma, whether there is a dose-effect relationship for dacarbazine, and whether non-dacarbazine-containing aggressive regimens are in any way superior to non-aggressive ones." | 9.10 | Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. ( Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D, 2002) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 9.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Forty-three patients with measurable disseminated cutaneous malignant melanoma, stages III-IV, and without previous cytotoxic chemotherapy or immunotherapy, were randomly allocated from 30 June 1980 to 30 November 1984, to receive either a schedule of procarbazine (100 mg/m2 p." | 9.06 | Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1986) |
| "Patients with stage III and IV melanoma were randomly assigned to receive procarbazine (100 mg/m2, Days 1--10), vinblastine (5 mg/m2, Days 1 and 8), and actinomycin D (0." | 9.04 | Procarbazine, vinblastine, and actinomycin D in stage III and IV melanoma with or without methanol-extracted residue of Bacillus Calmette-Guérin. ( Cuttner, J; De Bellis, R; Green, M; Kostinas, JE; Leone, LA; Pajak, TF; Vinciguerra, V, 1979) |
| "Patients with advanced malignant melanoma were randomly assigned to treatment with cylcophosphamide and vincristine (CV) or cyclophosphamide, vincristine, and procarbazine (CVP)." | 9.04 | Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma. ( Byrne, MJ, 1976) |
| "Forty-four consecutive ambulatory patients (24 male, 20 female; median age, 56 years [range, 21-76]) with evaluable disseminated malignant melanoma (stages III/IV) were entered in this study from October 1, 1975, to July 21, 1980 (last follow-up, October 31, 1983); they were treated with procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 1-10, vincristine (1." | 7.67 | Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1984) |
| "Twenty-one patients with metastatic melanoma were treated synchronously with procarbazine and radiotherapy." | 7.67 | Effective palliation of melanoma with procarbazine and radiotherapy given by a low-dose fractionation schedule. ( Abbott, RL; Ahmad, A; Gill, PG; Zeicmanis, J, 1986) |
| "Sixty-five previously untreated patients with metastatic malignant melanoma were treated with lomustine, vincristine, and procarbazine." | 7.67 | Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. ( Bodurtha, A; Iscoe, N; Paterson, A; Quirt, I; Russell, J; Shelley, W; Young, V, 1985) |
| "Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)." | 7.67 | Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987) |
| "Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%." | 7.66 | Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma. ( Dillman, RO; Green, MR; Horton, C, 1980) |
| "Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine." | 7.66 | Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. ( Carmo-Pereira, J; Costa, FO; Henriques, E; Pimentel, P, 1980) |
| "The aim of this randomized four-arm phase III study was to evaluate whether there is a difference in activity between regimens containing dacarbazine and regimens without dacarbazine in metastatic melanoma, whether there is a dose-effect relationship for dacarbazine, and whether non-dacarbazine-containing aggressive regimens are in any way superior to non-aggressive ones." | 5.10 | Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. ( Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D, 2002) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 5.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Forty-three patients with measurable disseminated cutaneous malignant melanoma, stages III-IV, and without previous cytotoxic chemotherapy or immunotherapy, were randomly allocated from 30 June 1980 to 30 November 1984, to receive either a schedule of procarbazine (100 mg/m2 p." | 5.06 | Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1986) |
| "Patients with stage III and IV melanoma were randomly assigned to receive procarbazine (100 mg/m2, Days 1--10), vinblastine (5 mg/m2, Days 1 and 8), and actinomycin D (0." | 5.04 | Procarbazine, vinblastine, and actinomycin D in stage III and IV melanoma with or without methanol-extracted residue of Bacillus Calmette-Guérin. ( Cuttner, J; De Bellis, R; Green, M; Kostinas, JE; Leone, LA; Pajak, TF; Vinciguerra, V, 1979) |
| "Patients with advanced malignant melanoma were randomly assigned to treatment with cylcophosphamide and vincristine (CV) or cyclophosphamide, vincristine, and procarbazine (CVP)." | 5.04 | Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma. ( Byrne, MJ, 1976) |
| "Forty-four consecutive ambulatory patients (24 male, 20 female; median age, 56 years [range, 21-76]) with evaluable disseminated malignant melanoma (stages III/IV) were entered in this study from October 1, 1975, to July 21, 1980 (last follow-up, October 31, 1983); they were treated with procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 1-10, vincristine (1." | 3.67 | Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1984) |
| "Twenty-one patients with metastatic melanoma were treated synchronously with procarbazine and radiotherapy." | 3.67 | Effective palliation of melanoma with procarbazine and radiotherapy given by a low-dose fractionation schedule. ( Abbott, RL; Ahmad, A; Gill, PG; Zeicmanis, J, 1986) |
| "Sixty-five previously untreated patients with metastatic malignant melanoma were treated with lomustine, vincristine, and procarbazine." | 3.67 | Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. ( Bodurtha, A; Iscoe, N; Paterson, A; Quirt, I; Russell, J; Shelley, W; Young, V, 1985) |
| "Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)." | 3.67 | Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987) |
| "Single-cell suspensions prepared from five human melanomas, grown serially as xenografts in athymic nude mice, were exposed in vitro to increasing concentrations of DTIC (Dacarbazine), CCNU (Lomustine), procarbazine, vinblastine, and the cancerostatic lectins abrin and ricin." | 3.66 | In vitro sensitivity of human melanoma xenografts to cytotoxic drugs. Correlation with in vivo chemosensitivity. ( Fodstad, O; Olsnes, S; Pihl, A; Tveit, KM, 1980) |
| "Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%." | 3.66 | Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma. ( Dillman, RO; Green, MR; Horton, C, 1980) |
| "Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine." | 3.66 | Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. ( Carmo-Pereira, J; Costa, FO; Henriques, E; Pimentel, P, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (89.47) | 18.7374 |
| 1990's | 2 (5.26) | 18.2507 |
| 2000's | 2 (5.26) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gasowska-Bajger, B | 1 |
| Wojtasek, H | 1 |
| TODD, ID | 1 |
| Stragand, JJ | 1 |
| Drewinko, B | 1 |
| Barlogie, B | 1 |
| Papadopoulous, N | 1 |
| White, RA | 1 |
| Carmo-Pereira, J | 3 |
| Costa, FO | 3 |
| Henriques, E | 3 |
| Jacquillat, C | 3 |
| Banzet, P | 2 |
| Maral, J | 3 |
| Tveit, KM | 2 |
| Fodstad, O | 4 |
| Olsnes, S | 1 |
| Pihl, A | 4 |
| Aass, N | 2 |
| Green, MR | 1 |
| Dillman, RO | 1 |
| Horton, C | 1 |
| Pimentel, P | 1 |
| Samuel, LM | 1 |
| Harvey, VJ | 1 |
| Mitchell, PL | 1 |
| Thompson, PI | 1 |
| Mak, D | 1 |
| Melville, P | 1 |
| Evans, BD | 1 |
| Jelić, S | 1 |
| Babovic, N | 1 |
| Kovcin, V | 1 |
| Milicevic, N | 1 |
| Milanovic, N | 1 |
| Popov, I | 1 |
| Radosavljevic, D | 1 |
| Schneider, I | 1 |
| Aulepp, H | 1 |
| Gartmann, H | 1 |
| Civatte, J | 1 |
| Puissant, A | 1 |
| Cottenot, F | 1 |
| Israel, L | 1 |
| Belaich, S | 1 |
| Chastang, C | 1 |
| Volm, M | 2 |
| Faufmann, M | 1 |
| MAttern, J | 2 |
| Wayss, K | 2 |
| Wilson, CB | 1 |
| Gutin, P | 1 |
| Boldrey, EB | 1 |
| Drafts, D | 1 |
| Levin, VA | 1 |
| Enot, KJ | 1 |
| Carl, W | 1 |
| Wittes, RE | 1 |
| Wittes, JT | 1 |
| Golbey, RB | 1 |
| Kostinas, JE | 1 |
| Leone, LA | 1 |
| Cuttner, J | 1 |
| Vinciguerra, V | 1 |
| Green, M | 1 |
| De Bellis, R | 1 |
| Pajak, TF | 1 |
| Kolarić, K | 1 |
| Malenica, B | 1 |
| Roth, A | 1 |
| Nordman, EM | 1 |
| Mäntylä, M | 1 |
| Didolkar, MS | 1 |
| Baffi, RR | 1 |
| Catane, R | 1 |
| Kaufman, J | 1 |
| Holyoke, ED | 1 |
| Byrne, MJ | 1 |
| Van Dyk, JJ | 1 |
| Falkson, G | 1 |
| Glover, DJ | 1 |
| Gill, PG | 1 |
| Abbott, RL | 1 |
| Ahmad, A | 1 |
| Zeicmanis, J | 1 |
| Wang, QL | 1 |
| Shelley, W | 1 |
| Quirt, I | 1 |
| Bodurtha, A | 1 |
| Iscoe, N | 1 |
| Russell, J | 1 |
| Paterson, A | 1 |
| Young, V | 1 |
| Repetto, L | 1 |
| Grimaldi, A | 1 |
| Ardizzoni, A | 1 |
| Sertoli, MR | 1 |
| Rosso, R | 1 |
| Dobrek, Z | 1 |
| Sellami, M | 1 |
| Weil, M | 1 |
| Auclerc, G | 1 |
| Dhermy, P | 1 |
| Aron-Rosa, D | 1 |
| Mechl, Z | 1 |
| Krejcí, P | 1 |
| Bonadonna, G | 1 |
| De Lena, M | 1 |
| Banfi, A | 1 |
| Lattuada, A | 1 |
| Luce, JK | 1 |
| Gutterman, JU | 1 |
| Mavligit, G | 1 |
| Gottlieb, JA | 1 |
| Burgess, MA | 1 |
| McBride, CE | 1 |
| Einhorn, L | 1 |
| Freireich, EJ | 1 |
| Hersh, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859] | Phase 2 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for procarbazine and Malignant Melanoma
| Article | Year |
|---|---|
Chemotherapy of malignant melanoma.
Topics: Alkylating Agents; Amides; Animals; Antigen-Antibody Reactions; Antimetabolites; Antineoplastic Agen | 1972 |
8 trials available for procarbazine and Malignant Melanoma
| Article | Year |
|---|---|
Clinical trials of chemotherapy and chemoimmunotherapy in primary malignant melanoma.
Topics: Clinical Trials as Topic; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Fema | 1982 |
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lomustine; Male; Melano | 1994 |
Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dose-Response | 2002 |
Combination chemotherapy in metastatic malignant melanoma: a randomized study of three DTIC-containing combination.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, | 1978 |
Procarbazine, vinblastine, and actinomycin D in stage III and IV melanoma with or without methanol-extracted residue of Bacillus Calmette-Guérin.
Topics: Antineoplastic Agents; BCG Vaccine; Bone Marrow; Clinical Trials as Topic; Dactinomycin; Digestive S | 1979 |
Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Fem | 1976 |
Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; H | 1986 |
[Clinical trials of chemotherapy and chemoimmunotherapy of malignant melanoma with unfavorable prognosis after surgical treatment].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical | 1985 |
29 other studies available for procarbazine and Malignant Melanoma
| Article | Year |
|---|---|
Indirect oxidation of the antitumor agent procarbazine by tyrosinase--possible application in designing anti-melanoma prodrugs.
Topics: Agaricales; Antineoplastic Agents; Hydrazines; Melanoma; Molecular Structure; Monophenol Monooxygena | 2008 |
NATULAN IN MANAGEMENT OF LATE HODGKIN'S DISEASE, OTHER LYMPHORETICULAR NEOPLASMS, AND MALIGNANT MELANOMA.
Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Humans; Hydrazines; Lymphoma; Lymphoma, Follic | 1965 |
Serial analysis of melanoma growth kinetics in a patient receiving bleomycin and procarbazine therapy: comparison of tumor volume, flow cytometry, and thymidine labeling techniques.
Topics: Autoradiography; Bleomycin; Cell Division; DNA, Neoplasm; Female; Flow Cytometry; Humans; Melanoma; | 1982 |
Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lomu | 1984 |
In vitro sensitivity of human melanoma xenografts to cytotoxic drugs. Correlation with in vivo chemosensitivity.
Topics: Abrin; Animals; Antineoplastic Agents; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; N | 1980 |
The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Dacarbazine; Drug Evaluation, Preclinical; | 1981 |
Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice.
Topics: Abrin; Animals; Antineoplastic Agents; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; N | 1980 |
Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lomustine; | 1980 |
Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Leukopenia; Lomustine; Male; Melanoma; Middle Aged; | 1980 |
An inverse relationship between the growth rate of human melanoma xenografts and their response to some cytostatic drugs.
Topics: Animals; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Neopl | 1980 |
[Histological and histochemical studies on melanoma metastases under immunobiological and cytostatic therapy].
Topics: Antineoplastic Agents; BCG Vaccine; Bleomycin; Cytarabine; Dinitrochlorobenzene; Fluorouracil; Human | 1976 |
Adjuvant chemotherapy or chemoimmunotherapy in the management of primary malignant melanoma of level III, IV, or V.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Bacterial Vaccines; BCG Vaccine; Dacarbazine; Drug | 1978 |
Sensitivity tests of tumors to cytostatic agents. I. Comparative investigations on transplanted tumors in vivo and in vitro.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cell Division; Cricetinae; Da | 1975 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Cancer chemotherapy and dentistry.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Asparaginase; Carci | 1977 |
A preliminary report of a pilot trial in adjuvant chemotherapy of primary melanoma.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Hu | 1979 |
Treatment of metastatic melanoma with combined 5-fluorouracil and procarbazine.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Melanoma; Middle Aged; N | 1977 |
Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
Topics: Dacarbazine; Drug Evaluation; Drug Resistance; Humans; Melanoma; Nitrosourea Compounds; Procarbazine | 1977 |
A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lu | 1975 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 1991 |
Effective palliation of melanoma with procarbazine and radiotherapy given by a low-dose fractionation schedule.
Topics: Brain Neoplasms; Combined Modality Therapy; Humans; Lymphatic Metastasis; Male; Melanoma; Palliative | 1986 |
[Various doses cisplatin combined with multi-drug chemotherapy of malignant solid tumors].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1989 |
Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; L | 1985 |
Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Female | 1987 |
[Adjuvant chemotherapy of intraocular malignant melanoma. Apropos of 20 cases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Procarbazin in advanced malignant melanoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Leukopenia; M | 1986 |
Secondary neoplasms in malignant lymphomas after intensive therapy.
Topics: Adult; Antineoplastic Agents; Follow-Up Studies; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; | 1973 |
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
Topics: Adult; Aged; Amides; Antibody Formation; Antineoplastic Agents; BCG Vaccine; Carmustine; Drug Therap | 1974 |
The effects of cytostatic drugs on transplanted tumours. An investigation of the correlation between in vivo and in vitro results.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Cytarabine; Dauno | 1974 |